

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 October 2020 (08.10.2020)



(10) International Publication Number
WO 2020/204828 A1

(51) International Patent Classification:

C07K 7/06 (2006.01) A61P 31/00 (2006.01)
A61K 38/08 (2019.01) A61P 35/00 (2006.01)
A61P 25/00 (2006.01)

(72) Inventors: NG, Simon; c/o p53 Laboratory, 8A Biomedical Grove, #06-04/05 Neuros, Singapore 138646 (SG).
BROWN, Christopher John; c/o p53 Laboratory, 8A Biomedical Grove, #06-04/05 Neuros, Singapore 138646 (SG).

(21) International Application Number:

PCT/SG2020/050192

(74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD;
P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(22) International Filing Date:

30 March 2020 (30.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201902892R 29 March 2019 (29.03.2019) SG


(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: PEPTIDES AND COMPOUNDS THAT BIND TO ELONGATION INITIATION FACTOR 4E

A

FIG. 1



(57) Abstract: The present invention relates to a peptide that binds to elongation initiation factor 4E (eIF4E) comprising the amino acid sequence CEX-1GX2X3X4X5C (SEQ ID NO: 1), where X-1 is an amino acid selected from the group consisting of threonine (T), methionine (M) or leucine (L), X2 and X3 is an amino acid selected from the group consisting of phenylalanine (F), modified phenylalanine and tyrosine (Y), X4 and X5 is any amino acid, wherein the two cysteine residues are joined by a disulphide bond. The peptides defined herein may be useful for treating a condition associated with dysregulated cap-dependent translation, such as cancer, infectious disease, autism or fragile X syndrome.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*